Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR

Cassio M. Fontes, Barbara D. Lipes, Jason Liu, Krystle N. Agans, Aiwei Yan, Patricia Shi, Daniela F. Cruz, Garrett Kelly, Kelli M. Luginbuhl, Daniel Y. Joh, Stephanie L. Foster, Jacob Heggestad, Angus Hucknall, Maiken H. Mikkelsen, Carl F. Pieper, Roarke W. Horstmeyer, Thomas W. Geisbert, Michael D. Gunn, Ashutosh Chilkoti

Research output: Contribution to journalArticlepeer-review


Ebola virus (EBOV) hemorrhagic fever outbreaks have been challenging to deter due to the lack of health care infrastructure in disease-endemic countries and a corresponding inability to diagnose and contain the disease at an early stage. EBOV vaccines and therapies have improved disease outcomes, but the advent of an affordable, easily accessed, mass-produced rapid diagnostic test (RDT) that matches the performance of more resource-intensive polymerase chain reaction (PCR) assays would be invaluable in containing future outbreaks. Here, we developed and demonstrated the performance of a new ultrasensitive point-of-care immunoassay, the EBOV D4 assay, which targets the secreted glycoprotein of EBOV. The EBOV D4 assay is 1000-fold more sensitive than the U.S. Food and Drug Administration approved RDTs and detected EBOV infection earlier than PCR in a standard nonhuman primate model. The EBOV D4 assay is suitable for low-resource settings and may facilitate earlier detection, containment, and treatment during outbreaks of the disease.

Original languageEnglish (US)
Article numberabd9696
JournalScience Translational Medicine
Issue number588
StatePublished - Apr 7 2021

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR'. Together they form a unique fingerprint.

Cite this